The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: A British society bone marrow transplantation study

Hematology

Volumn 13, Issue 2, 2008, Pages 119-127

  Gilleece, Maria H ^a   Pearce, Rachel ^b   Linch, David C ^c   Wilson, Marie ^b   Towison, Keiren ^b   Mackinnon, Stephen ^d   Potter, Michael ^e   Kazmi, Majid ^b   Gribben, John G ^f   Marks, David I ^g  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^d ROYAL FREE HOSPITAL   (United Kingdom)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f ROYAL LONDON HOSPITAL   (United Kingdom)

^g UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Allogeneic; Autologous; Lymphoplasmacytic lymphoma; Survival; Transplantation

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; STEROID; THALIDOMIDE; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE FREE INTERVAL; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; FOLLOW UP; GRAFT FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; KARNOFSKY PERFORMANCE STATUS; LYMPHOMA; LYMPHOPLASMACYTIC LYMPHOMA; MALE; MONOTHERAPY; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION; TREATMENT RESPONSE; UNITED KINGDOM;

ADULT; FEMALE; GREAT BRITAIN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; REGISTRIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; WALDENSTROM MACROGLOBULINEMIA;

EID: 48749128266     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453308X315915     Document Type: Article

References (38)

1. NCCN practice guidelines for multiple myeloma. National Comprehensive Cancer Network. Oncology (Huntingt) 1998; 12: 317-351.
2. Anon. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkins lymphoma. The Non-Hodgkins Lymphoma Classification Project. Blood 1997; 89: 3909-3918.
3. Gertz MA. Waldenstrom's macroglobulinemia: A review of therapy. Leuk Lymphoma 2002; 43: 1517-1526.
4. Ghobrial IM, Witzig TE. Waldenstrom macroglobulinemia. Curr Treat Options Oncol 2004; 5: 239-247.
5. Johnson SA, Oscier DG, Leblond V. Waldenstrom's macroglobulinaemia. Blood Rev 2002; 16: 175-184.
6. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M. Waldenstrom's macroglobulinemia: Clinical features, complications, and management. J Clin Oncol 2000; 18: 214-226.
7. UK CSLG, France GCLM, Germany CSG, Australasia LLG. A randomised trial of chlorambucil versus fludarabine as initial therapy of Waldenstroms's macroglobulinaemia and splenic lymphoma with villous lymphocytes. Available at: http://www.waldenstroms.org, 2005.
8. Gertz MA, Anagnostopoulos A, Anderson K et al. Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30: 121-126.
9. Desikan R, Li Z, Jagannath S. Waldenstrom's macroglobulinaemia: Current therapy and future approaches. BioDrugs 2002; 16: 201-207.
10. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and genetics of tumours of haematopoietic and lymphoid tissue. Lyon: IARC Press, 2001.
11. Durrant IJ, Prentice HG, Richards SM. Intensification of treatment for adults with acute lymphoblastic leukaemia: Results of U.K. Medical Research Council randomized trial UKALL XA. Medical Research Council Working Party on Leukaemia in Adults. Br J Haematol 1997; 99: 84-92.
12. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
13. Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
14. van OS R, Robinson S, Sheridan T, Mislow JMK, Dawes D, Mauch PM. Granulocyte colony-stimulating factor enhances bone marrow stem cell damage caused by repeated administration of cytotoxic agents. Blood 1998; 92: 1950-1956.
15. Dreger P, Kloss M, Petersen B et al. Autologous progenitor cell transplantation: Prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995; 86: 3970-3978.
16. Boccadoro M, Palumbo A, Bringhen S et al. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 2002; 87: 846-850.
17. Desikan R, Dhodapkar M, Siegel D et al. High-dose therapy with autologous haemopoietic stem cell support for Waldenstrom's macroglobulinaemia. Br J Haematol 1999; 105: 993-996.
18. Munshi NC, Barlogie B. Role for high-dose therapy with autologous hematopoietic stem cell support in Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30: 282-285.
19. Yang L, Wen B, Li H et al. Autologous peripheral blood stem cell transplantation for Waldenstrom's macroglobulinemia. Bone Marrow Transplant 1999; 24: 929-930.
20. Dreger P, Glass B, Kuse R et al. Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenstrom's macroglobulinaemia. Br J Haematol 1999; 106: 115-118.
21. Anagnostopoulos A, Giralt S. Stem cell transplantation (SCT) for Waldenstrom's macroglobulinemia (WM). Bone Marrow Transplant 2002; 29: 943-937.
22. Lahuerta JJ, Martinez-Lopez J, Serna JD et al. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000; 109: 438-446.
23. Brown JR, Yeckes H, Friedberg JW et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma J Clin Oncol 2005; 23: 2208-2214
24. Madan R, Chang V, Yook C. Waldenstrom macroglobulinaemia evolving into acute lymphoblastic leukemia: A case report and a review of the literature. Leukemia 2003; 18: 1433-1435.
25. Micallef IN, Lillington DM, Apostolidis J et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 2000; 18: 947-955
26. Hosing C, Munsell M, Yazji S et al. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol 2002; 13: 450-459.
27. Milligan DW, Kochethu G, Dearden C, Matutes E, MacConkey C, Catovsky D. High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemia. Br J Haematol 2006; 133: 173-175.
28. Leone G, Voso MT, Sica S, Morosetti R, Pagano L. Therapy related leukemias: Susceptibility, prevention and treatment. Leuk Lymphoma 2001; 41: 255-276.
29. Sorror ML, Maris MB, Storb R et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919.
30. Parimon T, Au DH, Martin PJ, Chien JW. A risk score for mortality after allogeneic hematopoietic sell transplantation. Ann Intern Med 2006; 144: 407-414.
31. Ueda T, Hatanaka K, Kosugi S, Kishino BI, Tamaki T. Successful non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT) for Waldenstrom's macroglobulinemia with severe pancytopenia. Bone Marrow Transplant 2001; 28: 609-611.
32. Tournilhac O, Leblond V, Tabrizi R et al. Transplantation in Waldenstrom's macroglobulinemia - the French experience. Semin Oncol 2003; 30: 291-296.
33. Anagnostopoulos A, Dimopoulos MA, Aleman A et al. High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia. Bone Marrow Transplant 2001; 27: 1027-1029.
34. Anagnostopoulos A, Hari PN, Perez WS et al. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. Biol Blood Marrow Transplant 2006; 12: 845-854.
35. van Besien K, Rowlings PA, Murphy SC et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998; 92: 1832-1836.
36. Kim DH, Won DI, Lee NY, Sohn SK, Suh JS, Lee KB. Non-CD34(+) Cells, especially CD8(+) cytotoxic T cells and CD56(+) natural killer cells, rather than CD34 cells, predict early engraftment and better transplantation outcomes in patients with hematologic malignancies after allogeneic peripheral stem cell transplantation. Biol Blood Marrow Transplant 2006; 2: 719-728.
37. Niederwieser D, Maris M, Shizuru JA et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620-1629.
38. Gopal AK, Pagel JM, Rajendran JG et al. Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy. Biol Blood Marrow Transplant 2006; 12: 697-702.